It was a pleasure to discuss with Prof. Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) his highlights from the psoriasis session he chaired at the EADV Spring Symposium, 6-7 May 2021.
- Could you give us a brief overview of the presentations on the psoriasis session that you chaired at EADV? (0:18)
- How has our increased understanding of the pathophysiological processes underlying psoriasis improved our management of the condition? (1:04)
- What unusual presentations of psoriasis have been highlighted? (2:08)
- What have been the most exciting developments in treatment strategies for psoriasis? (2:26)
Disclosures: Tiago Torres has acted as a consultant, advisor, or speaker for Abbvie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers-Squibb, Celgene, Janssen, LEO Pharma, Eli-Lilly, MSD, Mylan, Novartis, Pfizer, Sandoz, Samsung-Bioepis, UCB and Viatris.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of EADV Spring Symposium 2021 (Virtual).
Share this Video
Related Videos In Psoriasis
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Siew Eng Choon, AAD VMX 2021: Unmet Needs in Generalised Pustular Psoriasis
It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the current unmet needs in the treatment of generalised pustular psoriasis (GPP). Disclosures: Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, […]
Siew Eng Choon, AAD VMX 2021: Spesolimab in Generalised Pustular Psoriasis
It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the first RCT trial conducted in generalised pustular psoriasis (GPP). Effisayil 1 (NCT03782792) is a Phase 2 trial investigating the anti-IL-36 receptor antibody, spesolimab. The abstract entitled ‘Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!